文献速递妇科

卵巢癌初次肿瘤细胞减灭术后肉眼残留病灶相关的生活方式与个人因素

Lifestyle and personal factors associated with having macroscopic residual disease after ovarian cancer primary cytoreductive surgery.
PubMed 文献 · Gynecol Oncol · 2022-11-17

基于卵巢癌协会联盟2054例晚期高级别浆液性卵巢癌患者数据,分析12项生活方式与个人暴露与初次肿瘤细胞减灭术后肉眼残留病灶的关联。绝经期单用雌激素治疗与残留病灶风险降低33%相关(OR=0.67,95%CI 0.46-0.97,p=0.033);未母乳喂养的经产妇较未产妇残留病灶风险降低36%(OR=0.64,95%CI 0.43-0.94,p=0.022)。作者认为若上述关联被重复验证,这些因素可纳入风险分层模型。

要点

  • 绝经期单用雌激素治疗与肉眼残留病灶风险降低相关(OR=0.67,95%CI 0.46-0.97)。
  • 未母乳喂养的经产妇较未产妇残留病灶风险降低(OR=0.64,95%CI 0.43-0.94)。
  • 母乳喂养的经产妇与未产妇间无显著关联(OR=0.90,95%CI 0.65-1.25,p=0.53)。

核心结论

  • 绝经期单用雌激素治疗与无肉眼残留病灶的关联在生物学上合理,源于该暴露与高级别浆液性卵巢癌诊断之间的强生物学假设。
  • 若雌激素治疗或产次发现被重复验证,这些因素可纳入风险分层模型,以决定高级别浆液性卵巢癌患者应接受初次肿瘤细胞减灭术还是新辅助化疗。

研究设计与样本

  • 使用卵巢癌协会联盟2054例晚期高级别浆液性卵巢癌患者数据的分析。
  • 分析12项已知与卵巢癌风险或炎症相关的生活方式与个人暴露:体重指数、母乳喂养、口服避孕药使用、醋酸甲羟孕酮使用、子宫内膜异位症、卵巢癌一级亲属家族史、不完全妊娠、绝经期激素治疗使用、绝经状态、产次、吸烟、输卵管结扎。
  • 拟合逻辑回归模型评估上述暴露与初次肿瘤细胞减灭术后残留病灶的关联。

主要发现

  • 绝经期单用雌激素治疗者较从未使用者肉眼残留病灶风险降低33%(OR=0.67,95%CI 0.46-0.97,p=0.033)。
  • 未母乳喂养的经产妇较未产妇残留病灶风险降低36%(OR=0.64,95%CI 0.43-0.94,p=0.022)。
  • 母乳喂养的经产妇与未产妇间无显著关联(OR=0.90,95%CI 0.65-1.25,p=0.53)。

关键数值与推荐

  • 绝经期单用雌激素治疗 vs 从未使用:OR=0.67,95%CI 0.46-0.97,p=0.033。
  • 未母乳喂养经产妇 vs 未产妇:OR=0.64,95%CI 0.43-0.94,p=0.022。
  • 母乳喂养经产妇 vs 未产妇:OR=0.90,95%CI 0.65-1.25,p=0.53。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The presence of macroscopic residual disease after primary cytoreductive surgery (PCS) is an important factor influencing survival for patients with high-grade serous ovarian cancer (HGSC). More research is needed to identify factors associated with having macroscopic residual disease. We analyzed 12 lifestyle and personal exposures known to be related to ovarian cancer risk or inflammation to identify those associated with having residual disease after surgery. METHODS: This analysis used data on 2054 patients with advanced stage HGSC from the Ovarian Cancer Association Consortium. The exposures were body mass index, breastfeeding, oral contraceptive use, depot-medroxyprogesterone acetate use, endometriosis, first-degree family history of ovarian cancer, incomplete pregnancy, menopausal hormone therapy use, menopausal status, parity, smoking, and tubal ligation. Logistic regression models were fit to assess the association between these exposures and having residual disease following PCS. RESULTS: Menopausal estrogen-only therapy (ET) use was associated with 33% lower odds of having macroscopic residual disease compared to never use (OR = 0.67, 95%CI 0.46-0.97, p = 0.033). Compared to nulliparous women, parous women who did not breastfeed had 36% lower odds of having residual disease (OR = 0.64, 95%CI 0.43-0.94, p = 0.022), while there was no association among parous women who breastfed (OR = 0.90, 95%CI 0.65-1.25, p = 0.53). CONCLUSIONS: The association between ET and having no macroscopic residual disease is plausible given a strong underlying biologic hypothesis between this exposure and diagnosis with HGSC. If this or the parity finding is replicated, these factors could be included in risk stratification models to determine whether HGSC patients should receive PCS or neoadjuvant chemotherapy.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Phung MT, Webb PM, DeFazio A, et al. Lifestyle and personal factors associated with having macroscopic residual disease after ovarian cancer primary cytoreductive surgery. Gynecol Oncol. 2022. PMID: 36401943. doi:10.1016/j.ygyno.2022.10.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。